Published in J Nucl Med on May 01, 2002
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging (2004) 2.21
18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging (2003) 1.10
Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med Mol Imaging (2003) 0.99
Immunotargeting and cloning of two CD34 variants exhibiting restricted expression in adult rat endothelia in vivo. Am J Physiol Lung Cell Mol Physiol (2009) 0.92
In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. Br J Cancer (2003) 0.86
Ubiquitous yet distinct expression of podocalyxin on vascular surfaces in normal and tumor tissues in the rat. J Vasc Res (2009) 0.83
Investigation of a potential scintigraphic tracer for imaging apoptosis: radioiodinated annexin V-Kunitz protease inhibitor fusion protein. J Biomed Biotechnol (2011) 0.77
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med (2004) 2.89
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys (2002) 2.76
High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys (2002) 2.65
Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med (2002) 2.21
Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys (2005) 2.02
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 1.99
Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys (2005) 1.89
Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol (2003) 1.87
Measurement of lung tumor motion using respiration-correlated CT. Int J Radiat Oncol Biol Phys (2004) 1.74
Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med (2007) 1.72
Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys (2008) 1.64
Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys (2005) 1.56
Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.56
A patient-specific respiratory model of anatomical motion for radiation treatment planning. Med Phys (2007) 1.56
Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia (2009) 1.52
Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys (2007) 1.50
Validation of GATE Monte Carlo simulations of the GE Advance/Discovery LS PET scanners. Med Phys (2006) 1.48
Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res (2007) 1.45
The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med (2004) 1.44
Feasibility of ex vivo FDG PET of the colon. Radiology (2009) 1.43
Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol (2002) 1.41
Deep-inspiration breath-hold PET/CT of the thorax. J Nucl Med (2007) 1.39
Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging (2003) 1.34
Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm (2003) 1.31
Quantitative modeling of Cerenkov light production efficiency from medical radionuclides. PLoS One (2012) 1.29
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med (2010) 1.27
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol (2009) 1.23
The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys (2008) 1.22
Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Phys Med Biol (2009) 1.22
PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med (2004) 1.22
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res (2007) 1.20
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging (2013) 1.20
H2A.Z and H3.3 histone variants affect nucleosome structure: biochemical and biophysical studies. Biochemistry (2009) 1.19
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. J Nucl Med (2011) 1.18
Comparison of intensity-modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiforme. Med Dosim (2003) 1.17
Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study. Int J Radiat Oncol Biol Phys (2009) 1.17
Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys (2009) 1.16
Reduction of respiratory motion artifacts in PET imaging of lung cancer by respiratory correlated dynamic PET: methodology and comparison with respiratory gated PET. J Nucl Med (2003) 1.15
PET performance measurements for an LSO-based combined PET/CT scanner using the National Electrical Manufacturers Association NU 2-2001 standard. J Nucl Med (2004) 1.15
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med (2008) 1.15
Development of an image-guided robot for small animal research. Comput Aided Surg (2007) 1.15
Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol (2007) 1.14
Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat Oncol Biol Phys (2009) 1.13
Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer. J Nucl Med (2009) 1.12
18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J Nucl Med (2011) 1.11
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging (2014) 1.10
Observation of interfractional variations in lung tumor position using respiratory gated and ungated megavoltage cone-beam computed tomography. Int J Radiat Oncol Biol Phys (2007) 1.10
124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med (2011) 1.08
Intensity-modulated radiotherapy. Cancer J (2002) 1.07
Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. Cancer Res (2008) 1.07
Divergent modes of glycan recognition by a new family of carbohydrate-binding modules. J Biol Chem (2008) 1.07
In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin Cancer Res (2007) 1.06
Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer (2002) 1.05
Effect of motion on tracer activity determination in CT attenuation corrected PET images: a lung phantom study. Med Phys (2005) 1.04
Hypoxia in microscopic tumors. Cancer Lett (2008) 1.04
Deep-inspiration breath-hold PET/CT: clinical findings with a new technique for detection and characterization of thoracic lesions. J Nucl Med (2007) 1.04
Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Res (2003) 1.02
PET of hypoxia: current and future perspectives. J Nucl Med (2012) 1.02
Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol (2005) 1.00
Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol (2002) 1.00
Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer. Semin Oncol (2003) 1.00
A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. Eur J Nucl Med Mol Imaging (2004) 0.99
Imaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET. Radiology (2008) 0.97
Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med (2004) 0.96
Accuracy and precision of radioactivity quantification in nuclear medicine images. Semin Nucl Med (2012) 0.96
Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther (2007) 0.95
Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol (2002) 0.94
Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer Biother Radiopharm (2005) 0.94
Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys (2009) 0.94
High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia. J Nucl Med (2010) 0.93
Accuracy and reproducibility of tumor positioning during prolonged and multi-modality animal imaging studies. Phys Med Biol (2008) 0.93
In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression. Nucl Med Biol (2009) 0.93
Visualization of experimental lung and bone metastases in live nude mice by X-ray micro-computed tomography. Technol Cancer Res Treat (2006) 0.93
The effect of mild temperature hyperthermia on tumour hypoxia and blood perfusion: relevance for radiotherapy, vascular targeting and imaging. Int J Hyperthermia (2010) 0.92